A retrospective feasibility study of biweekly docetaxel in patients with high-risk metastatic castration-naïve prostate cancer

BACKGROUND: Results from randomized phase III trials have shown that thrice-weekly docetaxel added to androgen-deprivation therapy (ADT) has a significant impact on the survival of patients with metastatic castration-naïve prostate cancer (mCNPC) and established early chemotherapy as part of the sta...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoon, Sang Eun, Kim, Youjin, Cho, Jangho, Kang, Minyong, Sung, Hyun Hwan, Jeon, Hwang Gyun, Jeong, Byoung Chang, Seo, Seong Il, Jeon, Seong Soo, Lee, Hyun Moo, Choi, Han Yong, Lee, Su Jin, Park, Se Hoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499987/
https://www.ncbi.nlm.nih.gov/pubmed/31053137
http://dx.doi.org/10.1186/s12894-019-0463-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499987/
https://www.ncbi.nlm.nih.gov/pubmed/31053137
http://dx.doi.org/10.1186/s12894-019-0463-7

Ejemplares similares